Myriad Business Model Canvas

Co-development with pharmaceutical and biotech partners enables Myriad to deliver companion diagnostics that accelerate targeted therapy development and trial enrollment; the companion diagnostics market exceeded $5 billion in 2024 and FDA had approved over 40 companion diagnostics by 2024. Regulatory-aligned studies directly link test results to drug response and safety, supporting label expansions. Commercial agreements bundle testing with therapy access programs and real-world evidence generation enhances market penetration and reimbursement negotiations.

Partnerships with 20+ academic and clinical centers and access to 200,000+ biospecimens drive biomarker validation and 150+ peer-reviewed papers. Hospital and EHR integrations (96% US adoption 2024) streamline orders and results. Pharma co-development supports companion diagnostics in a >$5B market (2024). Payer contracts and ACO pilots secure coverage and cost-offset evidence.

Operating high-throughput pipelines for alignment, variant calling and annotation, Myriad curates internal and public resources (ClinVar >1.8 million submissions in 2024) and applies ACMG/AMP criteria for standardized interpretation; machine learning models boost classification sensitivity and reduce VUS rates, while clinician-friendly, actionable reports summarize pathogenicity, evidence and recommended follow-up for tens of thousands of tests processed annually.

Design and update clinical panels (25-gene myRisk, 12-gene GeneSight) with CLIA/CAP labs, processing tens of thousands of tests annually and publishing 30+ peer-reviewed studies by 2024. Maintain high-throughput sequencing, ML-supported interpretation (ClinVar >1.8M submissions in 2024) and QA/QC for clinical-grade reports. Manage 20+ regulatory filings/year, payer negotiations, prior-authorization workflows, and HIPAA/GDPR-compliant security (avg breach cost 4.45M USD 2024).

Multidisciplinary teams at Myriad combine molecular biology, oncology, genetics and data science, backed by the company’s 33+ years in hereditary testing and nationwide reach across all 50 states. Board-certified genetic counselors provide patient and provider support. Regulatory and quality experts maintain CLIA and CAP compliance. Field medical teams translate scientific advances into clinical practice.

Myriad’s CLIA/CAP labs process tens of thousands of samples monthly (2024), maintaining reproducible workflows and geographically redundant sites. Variant knowledgebases support ~35% diagnostic yield in rare disease cohorts (2024) and longitudinal real-world data feeds continuous model improvement. 2024 revenue ~$563M, petabyte storage, 99.99% SLA, AES‑256, SOC 2 Type II, Epic 31% / Cerner 25% market share.

Optimized logistics and automation trim lab turnaround by about 30%, cutting wait times for results; predictable SLAs (24–48 hour targets for priority oncology tests) support time-sensitive treatment decisions. Digital portals with ~95% uptime give real-time status visibility, and consistent performance reduces provider workflow delays by roughly 40%.

Tests turn sequencing into actionable care, backed by 30+ years and validated sensitivity 98%/specificity 96% (2024).

Automation trims TAT ~30%; priority oncology SLA 24–48h; portals ~95% uptime; workflow delays cut ~40%.

Genetic counseling in >75% pathways (2024); prior auth 40% faster (2024); APIs tap $1.8B healthcare API market (2024).

Genetic counseling guides patients through complex results with one-on-one sessions; financial assistance and payment plans can cover up to 100% of test costs for eligible patients to increase access; multilingual materials in over 10 languages improve equity and comprehension; secure patient portals provide 24/7 access to results, educational resources and follow-up scheduling.

Dedicated strategic reps and onboarding support 6,000 hospitals and thousands of outpatient practices with regular business reviews; MSLs supported 1,500+ provider engagements and >300 tumor boards to drive guideline-concordant use; digital portals enabled 68% of orders, APIs automated 42% of tasks and dashboards raised utilization visibility by 55%.

Secure digital portals manage orders, tracking, and reporting while APIs enable lab-to-lab and partner integrations; in 2024 APIs now power roughly 70% of clinical lab integrations, accelerating data exchange. Self-service tools reduce admin overhead and turnaround times, and role-based access controls ensure PHI protection in line with HIPAA requirements.

Field teams, health-system contracting, and conference presence drive referral volume and clinician adoption; ASCO reach 30–40k and booth costs $20k–$150k. Embedded EHR order sets and FHIR/HL7 integrations reduce deployment time; APIs power ~70% of lab integrations. Digital portals and role-based access ensure HIPAA-compliant workflows; Medicare Advantage covers >30M lives in 2024.

Pharmacogenomics guides antidepressant and CNS medication selection, addressing that up to 50% of patients do not respond to first-line antidepressants. Clinicians use PGx to reduce trial-and-error prescribing and cut adverse drug reactions by roughly 20–30% in published cohorts. Primary care demands simple workflows and clinician education for adoption. Payers prioritize measurable adherence gains (~20%) and demonstrated cost savings (reports up to $1,000 per patient).

Oncologists, cancer centers, and MDTs need rapid, actionable tumor profiling; US incident cancers ~1.96M in 2024 driving demand for standardized reports.

OB/GYNs/genetics use hereditary testing (BRCA ~1/400 overall; ~1/40 Ashkenazi) to change prevention and reproductive care per USPSTF/ACOG guidance.

Payers, PCPs, and pharma demand clinical utility, PGx (50% antidepressant nonresponse; ADRs ↓20–30%), value-based savings; IVD market ≈$120B (2024).

Compute, storage, and data transfer for pipelines often represent roughly 60% of cloud infrastructure spend, with enterprises in 2024 reporting cloud budgets up 20–30% year‑over‑year; software licensing and DevOps/platform engineering add another 15–25% of tech costs. Cybersecurity tools, monitoring, and incident response typically consume 10–15% of IT budgets, while compliance audits and data governance programs drive recurring spend—often in the low six‑figure range annually for regulated deployments.

R&D, trials and database curation drive steady fixed spend; in 2024 Myriad supported dozens of trials and hundreds of publications. Reagents and consumables are 40–60% of lab variable costs, with per-sample reagent costs ~$100–$500. Cloud, IT, compliance and field/org costs (conferences $50k–$150k) add significant recurring spend; GDPR fines €20M, HIPAA caps $1.9M.

Pharma partnerships hinge on regulatory milestones (FDA/CE approvals and PMAs achieved in 2024) driving companion diagnostic uptake; per-test revenues in 2024 industry benchmarks ran roughly $1,000–$2,500 linked to therapy use. Trial testing/site enablement generates service fees ($200–$1,200/sample) and site training; post-market surveillance and RWE collaborations in 2024 commonly yielded $0.5–5M contract values.

Revenue from payers (per-test reimbursement; US population ~333M in 2024) scales with coverage and prior authorization delays; patient self-pay aided by HDHPs (~33% of workers in 2024) adds out-of-pocket mix. Pharma/clinical trials drive premium per-test fees ($1,000–$2,500) and trial/sample fees ($200–$1,200). Health systems move toward bundled/capitated deals as MA enrollment >29M in 2024; RWE/data services tap a >$5B market.